Simpler Grants.gov #PAR-26-073

NIH NEI Translational Therapeutics Research Grant Opportunity

The National Institutes of Health (NIH), through the National Eye Institute (NEI), is seeking applications for its Translational Research Program for Therapeutics, focused on advancing laboratory research into treatments for visual system diseases. - Government Buyer: - National Institutes of Health (NIH) - National Eye Institute (NEI) - Program Scope: - Supports development of biological, pharmaceutical, medical device, and combination therapies for visual system disorders - Bi-phasic award structure: - R61 phase: up to two years for projects with strong preliminary data - R33 phase: up to three years for preclinical development and IND/IDE-enabling studies - Applicants must define clear, measurable milestones for each phase - Direct-to-R33 applications allowed for mature projects with evidence of a pre-IND/IDE FDA meeting - Eligibility: - Open to businesses, government agencies, educational institutions, and nonprofits - Notable Requirements: - No specific OEMs or vendors are named, as this is a research grant opportunity - Focus is on translational research and product development, not procurement of commercial products or services

Description

The NEI Translational Research program aims to rapidly translate innovative laboratory research into therapeutics for visual system diseases or disorders. It supports product development of biological, pharmaceutical, medical device, and combination therapies. The program uses a bi-phasic, milestone-driven award mechanism with an R61 phase up to two years for preliminary research and an R33 phase up to three years for final preclinical development and IND/IDE enabling studies. Milestones must be specific, measurable, achievable, relevant, and time-bound, and mature efforts may apply directly to the R33 phase with evidence of a pre-IND/IDE FDA meeting.

View original listing